drugset / Trial / NCT02719691
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase Ib study designed to evaluate the safety and toxicity of the combination of Alisertib and MLN0128 in patients with advanced solid tumors with an expansion cohort in patients with previously treated metastatic TNBC.
Timeline
- Start
- 2016-05-13
- Primary completion
- 2020-03-18
- Completion
- 2020-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alisertib | Small molecule | 30 mg | Oral |
| Subject | Alisertib | Small molecule | 40 mg | Oral |
| Subject | Sapanisertib | Small molecule | 1 mg | Oral |
| Subject | Sapanisertib | Small molecule | 2 mg | Oral |
| Subject | Sapanisertib | Small molecule | 3 mg | Oral |